Open AccessTREATMENT WITH ORAL ESTRONE SULPHATE IN THE FEMALE CLIMACTERIC
Author(s) -
Lagrelius A.
Publication year - 1981
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348109155464
Subject(s) - medicine , climacteric , estrone , endocrinology , alkaline phosphatase , bone mineral , estrogen , albumin , calcium , excretion , hematocrit , menopause , osteoporosis , chemistry , biochemistry , enzyme
. Thirty‐eight women were treated with estrone sulphate over a period of 30 months for climacteric problems. A random control group of 29 women were given methyl scopolamine. Bone mineral assays were performed by means of dual photon absorptiometry before the start of treatment and after 6, 12, 18, and 30 months. There was a difference in the mineral loss of trabecular bone between the two groups after 30 months of treatment, that of the control group being significantly higher (p>0.001). In the estrogen‐treated group there was a decrease in serum phosphorus (p>0.01), alkaline phosphatase activity (p>0.001), and albumin (p>0.001). In the control group, serum albumin showed the same decrease, while the other factors either showed no difference or even increased. The urinary excretion of calcium was not significantly reduced in the estrogen group, whereas there was an increase in the control group (p>0.01). There was an increase in hematocrit in both groups. Positive correlation was found between parity and loss of trabecular bone mineral (p>0.01).